Cargando…
Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease
Diabetic kidney disease (DKD), as the main complication of diabetes mellitus, is the primary cause of the end-stage renal disease (ESRD) and the most common chronic kidney disease. Overall, 30–40% of patients with type 1 and type 2 diabetes eventually develop DKD. Although some diabetes patients hav...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837569/ https://www.ncbi.nlm.nih.gov/pubmed/33519221 http://dx.doi.org/10.2147/DMSO.S288500 |
_version_ | 1783642981867192320 |
---|---|
author | Lu, Heng-Cheng Dai, Wen-Ni He, Li-Yu |
author_facet | Lu, Heng-Cheng Dai, Wen-Ni He, Li-Yu |
author_sort | Lu, Heng-Cheng |
collection | PubMed |
description | Diabetic kidney disease (DKD), as the main complication of diabetes mellitus, is the primary cause of the end-stage renal disease (ESRD) and the most common chronic kidney disease. Overall, 30–40% of patients with type 1 and type 2 diabetes eventually develop DKD. Although some diabetes patients have intensified glycemic control, they still develop diabetic kidney disease. Current treatment methods can alleviate but do not markedly halt disease development, resulting in renal failure and severe complications, even contributing to elevated morbidity and mortality rates. DKD is a disease with interactions of genes and the environment. Emerging evidence indicates that DKD-associated key genes are also regulated by the epigenetic mechanism. Recently, increasing researches involving cells and experimental animals demonstrated that histone post-translational modifications can mediate gene expression, which correlated with diabetic kidney disease. Novel therapeutic strategies for epigenetic events could be beneficial for the early detection and treatment of DKD to prevent it from developing into end-stage renal disease (ESRD). In this review, we discuss prior findings in the field of histone modifications in DKD, especially histone acetylation and histone methylation. We then focus on recent developments in histone acetylation and methylation involved in the pathogenesis of DKD. |
format | Online Article Text |
id | pubmed-7837569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78375692021-01-28 Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease Lu, Heng-Cheng Dai, Wen-Ni He, Li-Yu Diabetes Metab Syndr Obes Review Diabetic kidney disease (DKD), as the main complication of diabetes mellitus, is the primary cause of the end-stage renal disease (ESRD) and the most common chronic kidney disease. Overall, 30–40% of patients with type 1 and type 2 diabetes eventually develop DKD. Although some diabetes patients have intensified glycemic control, they still develop diabetic kidney disease. Current treatment methods can alleviate but do not markedly halt disease development, resulting in renal failure and severe complications, even contributing to elevated morbidity and mortality rates. DKD is a disease with interactions of genes and the environment. Emerging evidence indicates that DKD-associated key genes are also regulated by the epigenetic mechanism. Recently, increasing researches involving cells and experimental animals demonstrated that histone post-translational modifications can mediate gene expression, which correlated with diabetic kidney disease. Novel therapeutic strategies for epigenetic events could be beneficial for the early detection and treatment of DKD to prevent it from developing into end-stage renal disease (ESRD). In this review, we discuss prior findings in the field of histone modifications in DKD, especially histone acetylation and histone methylation. We then focus on recent developments in histone acetylation and methylation involved in the pathogenesis of DKD. Dove 2021-01-22 /pmc/articles/PMC7837569/ /pubmed/33519221 http://dx.doi.org/10.2147/DMSO.S288500 Text en © 2021 Lu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Lu, Heng-Cheng Dai, Wen-Ni He, Li-Yu Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease |
title | Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease |
title_full | Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease |
title_fullStr | Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease |
title_full_unstemmed | Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease |
title_short | Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease |
title_sort | epigenetic histone modifications in the pathogenesis of diabetic kidney disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837569/ https://www.ncbi.nlm.nih.gov/pubmed/33519221 http://dx.doi.org/10.2147/DMSO.S288500 |
work_keys_str_mv | AT luhengcheng epigenetichistonemodificationsinthepathogenesisofdiabetickidneydisease AT daiwenni epigenetichistonemodificationsinthepathogenesisofdiabetickidneydisease AT heliyu epigenetichistonemodificationsinthepathogenesisofdiabetickidneydisease |